US Pharma MarketingGilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
When Gilead Sciences rolled out its first sales projection Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a high-flying launch thus far.
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a high-flying launch thus far.
Source: FiercePharma